Clinical trial NCT02082054: StahistRx Phase 2, Five-arm, Parallel Group, Active vs Active, Double-blind Study
Official title: A Phase 2, Double-Blind, Parallel-Group, Dose-Ranging Study Evaluating Safety/ Efficacy Atropine Doses With Pseudoephedrine and Chlorpheniramine in SAR Patients 12 Years of Age and Older
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Rhinitis, Seasonal, Allergic
Keywords: rhinitis
seasonal
allergic
Lead sponsor: Magna Pharmaceuticals, Inc.
Sponsor class: INDUSTRY
First posted: 2014-03-10
Enrollment: 125
Sex: ALL
Minimum age (years): 12
Maximum age (years): 60
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This active vs active comparative trial will evaluate the safety and efficacy of incremental doses of atropine in combination with pseudoephedrine 120 mg/chlorpheniramine 8 mg in adult patients with a history of seasonal allergic rhinitis. Hypotheses are defined by total nasal symptom scores (TNSS) recorded by subjects in diaries where efficacy will be established by statistical significance where p \< 0.05.

Detailed description: Actives in each of the five study arms:

Pseudoephedrine 120 mg/Chlorpheniramine 8 mg/Atropine 0.36 mg Pseudoephedrine 120 mg/Chlorpheniramine 8 mg/Atropine 0.24 mg Pseudoephedrine 120 mg/Chlorpheniramine 8 mg/Atropine 0.12 mg Pseudoephedrine 120 mg/Chlorpheniramine 8 mg Atropine 0.24 mg

Eligibility criteria: Inclusion Criteria:

1. Male and females of any ethnic group between 12 and 60 years of age.
2. History of moderate to severe SAR for at least two years; defined as having a score of 2 or more on a 0-3 point scale
3. Documentation of sensitivity will be obtained from medical records or positive skin testing or in vitro specific IgE test.
4. Have a TNSS score of 6 with at least an average of 2.0 in the rhinorrhea sub-score during the placebo-run in phase.
5. Is a non-pregnant, non-lactating female who is postmenopausal, naturally or surgically sterile, or who agree to use effective contraceptive methods throughout the course of the study.
6. If female of childbearing potential, must agree to use listed acceptable birth control methods...
7. If female of childbearing potential, has a negative urine human chorionic gonadotropin (hCG) pregnancy test at screening
8. Is able to swallow whole tablets of orally administered medication
9. Is able to understand and provide signed informed consent

Exclusion Criteria:

1. Has asthma requiring corticosteroid treatment
2. Is currently undergoing chronic or intermittent use of inhaled, oral, intramuscular, intravenous, and/or potent or super potent topical corticosteroids
3. Has taken any of the following medications in the indicated time period prior to study enrolment:

   * Intranasal, opthalmic, or systemic corticosteroids (1 month)
   * Intranasal cromolyn (2 weeks)
   * Intranasal or systemic decongestants (3 days)
   * Intranasal or systemic antihistamines (7 days) or leukotriene inhibitors (7 days)
4. Documented evidence of acute or significant chronic sinusitis, as determined by the individual investigator
5. Has a history of allergic reaction to or known sensitivity to the active or inactive ingredients in the investigational products used in this study
6. Chronic use of concomitant medications (e.g., tricyclic antidepressants) that would affect assessment of the effectiveness of the study medication
7. Rhinitis medicamentosa
8. A history of glaucoma
9. Has known or suspected pregnancy, planned pregnancy, or lactation (for female patients)
10. Is currently receiving immunotherapy, unless at stable maintenance dose for at least 1 month.
11. Presence of a medical condition that might interfere with treatment evaluation or require a change in therapy.
12. Plans to travel outside the study area for a substantial portion of the study period
13. Has a history in the last 2 years or current evidence of abuse of illicit drugs, prescription medications, or alcohol that, in the opinion of the Investigator, would interfere with adherence to study requirements.
14. Has exposure to any investigational agent within 30 days prior to study entry.
15. Has clinically significant mental illness (to be determined by the Investigator)
16. Has a condition the Investigator believes would interfere with the ability to provide informed consent or comply with study instructions, or that might confound the interpretation of the study results or put the patient at undue risk

Primary outcomes:
measure: Dose-ranging data for atropin
timeFrame: 7.5 days
Secondary outcomes:
measure: Establish effect size for determining power and TNSS efficacy endpoint
timeFrame: 7.5 days
Other outcomes:
measure: Establish safety/efficacy and appropriate dosage interval of investigational formulas
timeFrame: 7.5 days
Locations:
city: Stockbridge
country: United States
facility: Clinical Research Atlanta
state: Georgia
city: Louisville
country: United States
facility: Family Allergy and Asthma Institute
state: Kentucky
city: Charleston
country: United States
facility: National Allergy, Asthma & Urticaria Centers of Charleston, PA
state: South Carolina
city: New Braunfels
country: United States
facility: Central Texas Health Research
state: Texas
Study officials:
affiliation: Family Allergy and Asthma
name: Stephen J Pollard, MD
role: PRINCIPAL_INVESTIGATOR
References: